VEGZELMA 25 mg/mL concentrate for solution for infusion

DRUG5 trials

Sponsors

Janssen Cilag International, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Academisch Ziekenhuis Maastricht, Daiichi Sankyo Inc., Genmab A/S

Conditions

KRAS/NRAS and BRAF Wildtype RecurrentMetastatic colorectal cancerOvarian CancerPatients with metastatic non-squamous NSCLC pre-treated with platinum-doublet chemotherapy and ICI (for those with targetable oncogenic driversRecurrent Platinum-Sensitive Ovarian CancerUnresectable or Metastatic Colorectal Cancerand active BMdefined as asymptomatic untreated or unequivocally progressive after local treatment

Phase 2

Sequential immunochemotherapy treatment with Pembrolizumab plus Dendritic Cell (DC) Vaccine followed by Trifluridine/Tipiracil plus Bevacizumab in refractory mismatch-repair-proficient (pMMR) or microsatellite-stable (MSS) metastatic colorectal cancer

RecruitingCTIS2024-514053-30-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Metastatic colorectal cancer

Start: 2025-01-07Target: 36Updated: 2024-11-07

A single arm phase II study evaluating intracranial efficacy of Sacituzumab govitecan (SG) with bevacizumab in patients with asymptomatic brain metastases from non-small cell lung cancer (NSCLC)

RecruitingCTIS2024-514066-40-00

Academisch Ziekenhuis Maastrichtand active BM, defined as asymptomatic untreated or unequivocally progressive after local treatment, Patients with metastatic non-squamous NSCLC pre-treated with platinum-doublet chemotherapy and ICI (for those with targetable oncogenic drivers +1

Start: 2025-07-10Target: 25Updated: 2025-03-17

Phase 3

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

RecruitingCTIS2024-513853-66-00

Janssen Cilag InternationalKRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

Start: 2025-02-04Target: 162Updated: 2026-01-07

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Verus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112)

RecruitingCTIS2024-516982-35-00

Daiichi Sankyo Inc.Ovarian Cancer

Start: 2025-09-11Target: 182Updated: 2026-01-21

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Not yet recruitingCTIS2025-524202-15-00

Genmab A/SRecurrent Platinum-Sensitive Ovarian Cancer

Target: 83Updated: 2026-09-18